Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Proton NMR characterization of intact primary and metastatic melanoma cells in 2D & 3D cultures.

Ramachandran GK, Yeow CH.

Biol Res. 2017 Mar 16;50(1):12. doi: 10.1186/s40659-017-0117-8.

2.

Amino Acid Profiles of Serum and Urine in Search for Prostate Cancer Biomarkers: a Pilot Study.

Dereziński P, Klupczynska A, Sawicki W, Pałka JA, Kokot ZJ.

Int J Med Sci. 2017 Jan 1;14(1):1-12. doi: 10.7150/ijms.15783. eCollection 2017 Jan 1.

3.

Metabolomics and its Application to the Development of Clinical Laboratory Tests for Prostate Cancer.

McDunn JE, Stirdivant SM, Ford LA, Wolfert RL.

EJIFCC. 2015 Mar 10;26(2):92-104. eCollection 2015 Mar 10.

4.

Biomarker Discovery in Human Prostate Cancer: an Update in Metabolomics Studies.

Lima AR, Bastos Mde L, Carvalho M, Guedes de Pinho P.

Transl Oncol. 2016 Aug;9(4):357-70. doi: 10.1016/j.tranon.2016.05.004. Review.

5.

Response of Degarelix treatment in human prostate cancer monitored by HR-MAS 1H NMR spectroscopy.

Madhu B, Shaw GL, Warren AY, Neal DE, Griffiths JR.

Metabolomics. 2016;12:120. Epub 2016 Jun 30.

6.

Recent Advances in Metabolic Profiling And Imaging of Prostate Cancer.

Thapar R, Titus MA.

Curr Metabolomics. 2014 Apr;2(1):53-69.

7.

Phorbol ester stimulates ethanolamine release from the metastatic basal prostate cancer cell line PC3 but not from prostate epithelial cell lines LNCaP and P4E6.

Schmitt J, Noble A, Otsuka M, Berry P, Maitland NJ, Rumsby MG.

Br J Cancer. 2014 Oct 14;111(8):1646-56. doi: 10.1038/bjc.2014.457. Epub 2014 Aug 19.

8.

Novel tools for prostate cancer prognosis, diagnosis, and follow-up.

Dimakakos A, Armakolas A, Koutsilieris M.

Biomed Res Int. 2014;2014:890697. doi: 10.1155/2014/890697. Epub 2014 May 4. Review.

9.

The role of metabolic imaging in radiation therapy of prostate cancer.

Zhang VY, Westphalen A, Delos Santos L, Tabatabai ZL, Shinohara K, Vigneron DB, Kurhanewicz J.

NMR Biomed. 2014 Jan;27(1):100-11. doi: 10.1002/nbm.3007. Epub 2013 Aug 12. Review.

10.

Spermine and citrate as metabolic biomarkers for assessing prostate cancer aggressiveness.

Giskeødegård GF, Bertilsson H, Selnæs KM, Wright AJ, Bathen TF, Viset T, Halgunset J, Angelsen A, Gribbestad IS, Tessem MB.

PLoS One. 2013 Apr 23;8(4):e62375. doi: 10.1371/journal.pone.0062375. Print 2013.

11.

Metabolomic imaging of prostate cancer with magnetic resonance spectroscopy and mass spectrometry.

Spur EM, Decelle EA, Cheng LL.

Eur J Nucl Med Mol Imaging. 2013 Jul;40 Suppl 1:S60-71. doi: 10.1007/s00259-013-2379-x. Epub 2013 Apr 3. Review.

12.

2-hydroxyglutarate as a magnetic resonance biomarker for glioma subtyping.

Esmaeili M, Vettukattil R, Bathen TF.

Transl Oncol. 2013 Apr;6(2):92-8. Epub 2013 Apr 1.

13.

High-resolution magic angle spinning 1H MRS in prostate cancer.

Decelle EA, Cheng LL.

NMR Biomed. 2014 Jan;27(1):90-9. doi: 10.1002/nbm.2944. Epub 2013 Mar 26. Review.

14.

Identification of plasma lipid biomarkers for prostate cancer by lipidomics and bioinformatics.

Zhou X, Mao J, Ai J, Deng Y, Roth MR, Pound C, Henegar J, Welti R, Bigler SA.

PLoS One. 2012;7(11):e48889. doi: 10.1371/journal.pone.0048889. Epub 2012 Nov 12.

15.

Choline-releasing glycerophosphodiesterase EDI3 links the tumor metabolome to signaling network activities.

Marchan R, Lesjak MS, Stewart JD, Winter R, Seeliger J, Hengstler JG.

Cell Cycle. 2012 Dec 15;11(24):4499-506. doi: 10.4161/cc.22544. Epub 2012 Oct 31.

16.

Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) expression correlates with malignant choline phospholipid metabolite profiles in human breast cancer.

Cao MD, Döpkens M, Krishnamachary B, Vesuna F, Gadiya MM, Lønning PE, Bhujwalla ZM, Gribbestad IS, Glunde K.

NMR Biomed. 2012 Sep;25(9):1033-42. doi: 10.1002/nbm.2766. Epub 2012 Jan 26.

17.

Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas.

Elkhaled A, Jalbert LE, Phillips JJ, Yoshihara HA, Parvataneni R, Srinivasan R, Bourne G, Berger MS, Chang SM, Cha S, Nelson SJ.

Sci Transl Med. 2012 Jan 11;4(116):116ra5. doi: 10.1126/scitranslmed.3002796.

18.
19.

Choline metabolism in malignant transformation.

Glunde K, Bhujwalla ZM, Ronen SM.

Nat Rev Cancer. 2011 Nov 17;11(12):835-48. doi: 10.1038/nrc3162. Review.

20.

Application of metabolomics to prostate cancer.

Trock BJ.

Urol Oncol. 2011 Sep-Oct;29(5):572-81. doi: 10.1016/j.urolonc.2011.08.002. Review.

Supplemental Content

Support Center